UveitisNCT07176130
Demographics and Clinical Characteristics of Ocular Inflammatory Diseases in Singapore
An observational study of Uveitis and Scleritis and Episcleritis, run by Singapore National Eye Centre at 1 site in Singapore.
Trial summary
This is a retrospective study analyzing demographics, clinical characteristics, treatment received, and outcomes of ocular inflammatory diseases that presented to the Singapore National Eye Centre (SNEC). Read more about this study
- Who is it for?
- Ages 21 to 99 years
- Conditions the study is for
- Uveitis, Scleritis and Episcleritis, Endophthalmitis
- How many people
- 200 participants
- Where
- 1 siteSingapore
- Study dates
- 19 Aug 2025to 30 Oct 2025
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 99 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients diagnosed with ocular inflammatory diseases, including masquerade syndromes such as ocular neoplasms (e.g., vitreoretinal and uveal lymphoma) and endophthalmitis, at the Singapore National Eye Centre.
Who may be able to join
- Patients diagnosed with uveitis
- Patients diagnosed with scleritis or episcleritis
- Patients diagnosed with ocular neoplasms e.g., vitreoretinal and uveal lymphoma
- Patients diagnosed with endophthalmitis
- Diagnosis confirmed by laboratory testing or histopathological examination
- Patients diagnosed and managed at the Singapore National Eye Centre (SNEC)
Who cannot join
- Patients with less than two years of clinical follow-up
- Patients with incomplete diagnostic confirmation (i.e., lacking laboratory or histopathological evidence)
- Patients diagnosed outside of Singapore National Eye Centre (SNEC)
- Cases with missing key clinical or outcome data
Trial locations and contacts
1 site in 1 country.
About this study
This is a retrospective study analyzing demographics, clinical characteristics, treatment received, and outcomes of ocular inflammatory diseases that presented to the Singapore National Eye Centre (SNEC).
Read the detailed description
This is a retrospective, cross-sectional study. In this study, the investigators aim to investigate demographics, clinical characteristics, treatment received, and outcomes of ocular inflammatory diseases, including masquerade syndromes such as ocular neoplasms (e.g., vitreoretinal and uveal lymphoma) and endophthalmitis that presented to the Singapore National Eye Centre (SNEC). Data on demographics, clinical features, diagnosis, investigations, secondary complications, treatment received, and outcomes will be analyzed using statistical software. The results of this study will lead to an improved clinical practice with better treatment selections and an optimized monitoring protocol for follow-up care for patients with ocular inflammatory diseases, including masquerade syndromes such as ocular neoplasms (e.g.,vitreoretinal and uveal lymphoma) and endophthalmitis. This will lead to better clinical outcomes and prevention of serious sight-threatening complications.
- Conditions
- Uveitis, Scleritis and Episcleritis, Endophthalmitis, Masquerade Syndromes, Intraocular Lymphoma
- Being tested
- No Intervention: Observational Cohort
- Keywords
- Uveitis, Scleritis, Masquerades syndromes, Intraocular lymphoma, Endophthalmitis
- Medical subject headings
- Uveitis, Scleritis, Endophthalmitis, Intraocular Lymphoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
No Intervention: Observational CohortOther
Not applicable, No intervention. Observational study.
| Study group | Role | What they receive |
|---|---|---|
| Uveitis | Patients diagnosed with uveitis at Singapore National Eye Centre Receives: Other: No Intervention: Observational Cohort | |
| Scleritis and Episcleritis | Patients diagnosed with scleritis or episcleritis at Singapore National Eye Centre Receives: Other: No Intervention: Observational Cohort | |
| Intraocular lymphoma | Patients diagnosed with ocular neoplasms at Singapore National Eye Centre Receives: Other: No Intervention: Observational Cohort | |
| Endophthalmitis | Patients diagnosed with endophthalmitis at Singapore National Eye Centre Receives: Other: No Intervention: Observational Cohort |
What is being measured
The primary outcome is the main question the study is designed to answer.
Distribution of demographics, diagnosis, clinical features, treatment and outcomes
Percentage ethnic distribution, percentage of gender distribution, percentage of age distribution, percentage of etiology, percentage of clinical features, percentage of investigations, percentage of diagnosis, percentage of secondary complications, percentage of treatment received, percentage of outcomes
Measured: January 1987 and January 2025
Secondary outcomes (1)
Correlation of demographics, diagnosis, clinical features, and treatment outcomes
To evaluate the independent and combined effects of demographic factors, diagnostic categories, and clinical features on treatment outcomes using multivariate logistic and cox regression analysis
Measured: January 1987 and January 2025
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Sep 2025
- Study start19 Aug 2025
- Primary completion30 Sep 2025 (estimated)
- Study completion30 Oct 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for UveitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Singapore National Eye Centre
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Samanthila Waduthantri, Singapore National Eye Centre
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07176130
- Sponsor's protocol ID
- 2019/2811
- Status last verified
- Sep 2025
- First submitted
- 30 Aug 2025
- Last updated
- 16 Sep 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: IPD will not be shared. Anonymous data.
Publications
Siak J, Jansen A, Waduthantri S, Teoh CS, Jap A, Chee SP. The Pattern of Uveitis among Chinese, Malays, and Indians in Singapore. Ocul Immunol Inflamm. 2017;25(sup1):S81-S93. doi: 10.1080/09273948.2016.1188968. Epub 2016 Jul 15.
PubMed 27419535Chee SP, Jap A. Endogenous endophthalmitis. Curr Opin Ophthalmol. 2001 Dec;12(6):464-70. doi: 10.1097/00055735-200112000-00012.
PubMed 11734687International Vitreoretinal B-Cell Lymphoma Registry Investigator Group. Presentation, Diagnostic Testing and Initial Treatment of Vitreoretinal Lymphoma. Ophthalmol Retina. 2024 Jan;8(1):72-80. doi: 10.1016/j.oret.2023.08.012. Epub 2023 Aug 28.
PubMed 37648063Carbonell D, Mahajan S, Chee SP, Sobolewska B, Agrawal R, Bulow T, Gupta V, Jones NP, Accorinti M, Agarwal M, Batchelor T, Biswas J, Cimino L, tenDam-van Loon NH, de-la-Torre A, Frenkel S, Pe'er J, Kramer M, Miserocchi E, Mochizuki M, Ness T, Rosenbaum JT, Sen HN, Simion M (VRL patient), Sitter H, Vasconcelos-Santos DV, Habot-Wilner Z, Coupland SE, Pulido JS, Smith J, Thorne JE, Zierhut M; Study Group for Vitreoretinal Lymphoma Diagnostics. Consensus Recommendations for the Diagnosis of Vitreoretinal Lymphoma. Ocul Immunol Inflamm. 2021 Apr 3;29(3):507-520. doi: 10.1080/09273948.2021.1878233. Epub 2021 May 19.
PubMed 34009095
Study at a glance
From the registry record, last updated by the sponsor on 16 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Demographics and Clinical Characteristics of Ocular Inflammatory Diseases in Singapore
- ClinicalTrials.gov ID
- NCT07176130
- Acronym / sponsor ID
- 2019/2811
- Conditions
- Uveitis, Scleritis and Episcleritis, Endophthalmitis, Masquerade Syndromes, Intraocular Lymphoma
- Keywords
- Uveitis, Scleritis, Masquerades syndromes, Intraocular lymphoma, Endophthalmitis
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Singapore National Eye CentreOther government
- Study start
- 19 Aug 2025 (actual)
- Primary completion
- 30 Sep 2025 (estimated)
- Study completion
- 30 Oct 2025 (estimated)
- First posted
- 16 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a retrospective study analyzing demographics, clinical characteristics, treatment received, and outcomes of ocular inflammatory diseases that presented to the Singapore National Eye Centre (SNEC).
Detailed description
This is a retrospective, cross-sectional study. In this study, the investigators aim to investigate demographics, clinical characteristics, treatment received, and outcomes of ocular inflammatory diseases, including masquerade syndromes such as ocular neoplasms (e.g., vitreoretinal and uveal lymphoma) and endophthalmitis that presented to the Singapore National Eye Centre (SNEC). Data on demographics, clinical features, diagnosis, investigations, secondary complications, treatment received, and outcomes will be analyzed using statistical software. The results of this study will lead to an improved clinical practice with better treatment selections and an optimized monitoring protocol for follow-up care for patients with ocular inflammatory diseases, including masquerade syndromes such as ocular neoplasms (e.g.,vitreoretinal and uveal lymphoma) and endophthalmitis. This will lead to better clinical outcomes and prevention of serious sight-threatening complications.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Uveitis | – | Other: No Intervention: Observational CohortPatients diagnosed with uveitis at Singapore National Eye Centre |
| Scleritis and Episcleritis | – | Other: No Intervention: Observational CohortPatients diagnosed with scleritis or episcleritis at Singapore National Eye Centre |
| Intraocular lymphoma | – | Other: No Intervention: Observational CohortPatients diagnosed with ocular neoplasms at Singapore National Eye Centre |
| Endophthalmitis | – | Other: No Intervention: Observational CohortPatients diagnosed with endophthalmitis at Singapore National Eye Centre |
Who may qualify
- Ages
- 21 to 99 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients diagnosed with ocular inflammatory diseases, including masquerade syndromes such as ocular neoplasms (e.g., vitreoretinal and uveal lymphoma) and endophthalmitis, at the Singapore National Eye Centre.
Key inclusion criteria (6 listed)
- Patients diagnosed with uveitis
- Patients diagnosed with scleritis or episcleritis
- Patients diagnosed with ocular neoplasms e.g., vitreoretinal and uveal lymphoma
- Patients diagnosed with endophthalmitis
- Diagnosis confirmed by laboratory testing or histopathological examination
Key exclusion criteria (4 listed)
- Patients with less than two years of clinical follow-up
- Patients with incomplete diagnostic confirmation (i.e., lacking laboratory or histopathological evidence)
- Patients diagnosed outside of Singapore National Eye Centre (SNEC)
- Cases with missing key clinical or outcome data
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| No Intervention: Observational CohortNot applicable, No intervention. Observational study. | Other | Endophthalmitis, Intraocular lymphoma, Scleritis and Episcleritis, Uveitis |
Primary outcome
Distribution of demographics, diagnosis, clinical features, treatment and outcomes
Time frame: January 1987 and January 2025
Percentage ethnic distribution, percentage of gender distribution, percentage of age distribution, percentage of etiology, percentage of clinical features, percentage of investigations, percentage of diagnosis, percentage of secondary complications, percentage of treatment received, percentage of outcomes
1 secondary outcome
Correlation of demographics, diagnosis, clinical features, and treatment outcomes
Time frame: January 1987 and January 2025
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Sep 2025.
- Background: PubMed 27419535Siak J, Jansen A, Waduthantri S, Teoh CS, Jap A, Chee SP. The Pattern of Uveitis among Chinese, Malays, and Indians in Singapore. Ocul Immunol Inflamm. 2017;25(sup1):S81-S93. doi: 10.1080/09273948.2016.1188968. Epub 2016 Jul 15.
- Background: PubMed 11734687Chee SP, Jap A. Endogenous endophthalmitis. Curr Opin Ophthalmol. 2001 Dec;12(6):464-70. doi: 10.1097/00055735-200112000-00012.
- Background: PubMed 37648063International Vitreoretinal B-Cell Lymphoma Registry Investigator Group. Presentation, Diagnostic Testing and Initial Treatment of Vitreoretinal Lymphoma. Ophthalmol Retina. 2024 Jan;8(1):72-80. doi: 10.1016/j.oret.2023.08.012. Epub 2023 Aug 28.
- Background: PubMed 34009095Carbonell D, Mahajan S, Chee SP, Sobolewska B, Agrawal R, Bulow T, Gupta V, Jones NP, Accorinti M, Agarwal M, Batchelor T, Biswas J, Cimino L, tenDam-van Loon NH, de-la-Torre A, Frenkel S, Pe'er J, Kramer M, Miserocchi E, Mochizuki M, Ness T, Rosenbaum JT, Sen HN, Simion M (VRL patient), Sitter H, Vasconcelos-Santos DV, Habot-Wilner Z, Coupland SE, Pulido JS, Smith J, Thorne JE, Zierhut M; Study Group for Vitreoretinal Lymphoma Diagnostics. Consensus Recommendations for the Diagnosis of Vitreoretinal Lymphoma. Ocul Immunol Inflamm. 2021 Apr 3;29(3):507-520. doi: 10.1080/09273948.2021.1878233. Epub 2021 May 19.
- Individual participant dataSharing planned: No. IPD will not be shared. Anonymous data.
Related trials for Uveitis
RecruitingPhase 3
A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis
Behçet's Disease, Juvenile Psoriatic Arthritis
Not yet recruiting
Efficacy and Safety of Adalimumab for the Treatment of Ocular Inflammation
Non-infectious Anterior Uveitis, Non-infectious Intermediate Uveitis
RecruitingObservational study
A Study of Uveitis in Children <18 Years of Age
Uveitis
Active, not recruitingPhase 2
Multicenter Study on the Efficacy and Safety of OCS-01 in Subjects With Uveitis Related and Post Surgical Macular Edema
Uveitis Related Cystoid Macular Edema, Cystoid Macular Edema, Postoperative
RecruitingPhase 1
A Proof-of-concept Trial to EvaluAte the efficaCy and Safety Of Cell Therapy TRX103 in Patients With Active, Non-infectious Uveitis
Non Infectious Uveitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Uveitis and Scleritis and Episcleritis, run by Singapore National Eye Centre at 1 site in Singapore.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 16 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Singapore. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Distribution of demographics, diagnosis, clinical features, treatment and outcomes (time frame: January 1987 and January 2025). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07176130, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Sep 2025.